Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456326 · ClinicalTrials.gov registry record
Heparin-Induced Thrombocytopenia Registry
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 242
- Enrollment target
NCT00456326: Completed study, sponsored by Brigham and Women's Hospital.
NCT00456326 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 242 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00456326 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortality rate. Retrospective 3 years, looking forward prospectively.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-08 |
What the finished NCT00456326 record still lists
NCT00456326 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00456326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00456326 about?
NCT00456326 is a clinical study titled "Heparin-Induced Thrombocytopenia Registry". The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortality rate. Retrospective 3 years, looking forward prospectively.
What is the current status of trial NCT00456326?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2005-10. Estimated completion is 2007-08.
Who is sponsoring clinical trial NCT00456326?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia